Skip to main content
Clinical Trials/NCT03913481
NCT03913481
Active, not recruiting
Not Applicable

Acute Normovolemic Hemodilution in High-risk Cardiac Surgery Patients. A Multicentre Randomized Trial.

Università Vita-Salute San Raffaele32 sites in 11 countries2,000 target enrollmentApril 15, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C.Surgical Procedure; Cardiac
Sponsor
Università Vita-Salute San Raffaele
Enrollment
2000
Locations
32
Primary Endpoint
RBCs transfusion
Status
Active, not recruiting
Last Updated
8 months ago

Overview

Brief Summary

Transfusions are one of the most overused treatments in modern medicine, and saving blood is one important issue all around the world. Cardiac surgery makes up a large percentage of the overall blood components consumption in surgery.

Acute normovolemic hemo-dilution (ANH) is a well-known strategy which has been used for years without the support of high quality evidence based medicine to improve post-cardiopulmonary bypass coagulation and reduce red blood cells (RBC) transfusion. We designed a multicenter randomized controlled trial to investigate the effect of ANH in reducing the number of cardiac surgery patients receiving RBC transfusions during hospital stay. We will randomize 2000 patients to have sufficient power to demonstrate a 20% relative and 7% absolute risk reduction in the number of patients' RBC transfusion. If the results of the study will confirm our hypothesis, this will have a great impact on blood management in cardiac operating room.

Registry
clinicaltrials.gov
Start Date
April 15, 2019
End Date
December 1, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Giovanni Landoni

MD, Associate Professor

Università Vita-Salute San Raffaele

Eligibility Criteria

Inclusion Criteria

  • Signed informed consent
  • Any cardiac surgical intervention on CPB
  • Elective surgery

Exclusion Criteria

  • Medical decision (e.g.: planned pre-CPB ANH considered undeniable for ethical reasons or not applicable for safety issues)
  • Unstable Coronary Artery Disease: Recent (\< 6 weeks) myocardial infarction, unstable angina, severe (\> 70%) left main coronary artery stenosis
  • Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or IABP, preoperative severe acute renal failure (anuria or oliguria \<10ml/hr.)
  • Emergency surgery
  • Pregnancy
  • Unfeasibility to withdraw ≥ 650 ml without inducing hemodynamic instability
  • Unfeasibility to withdraw ≥ 650 ml without inducing pre-CPB anemia (Htc \<30%)
  • Unfeasibility to withdraw ≥ 650 ml without inducing low Htc during CPB (Htc \<24%)

Outcomes

Primary Outcomes

RBCs transfusion

Time Frame: hospital discharge, an average of 10 days

The number of patients receiving RBCs transfusion after elective cardiac surgery.

Secondary Outcomes

  • Mortality(30 days)
  • Ischemic complications(hospital discharge,an average of 10 days)
  • AKI(hospital discharge, an average of 10 days)
  • Bleeding complications(hospital discharge, an average of 10 days)

Study Sites (32)

Loading locations...

Similar Trials